New aspects of natural-killer-cell surveillance and therapy of cancer

Nature Reviews Cancer

Volumn 2, Issue 11, 2002, Pages 850-861

  Smyth, Mark J ^a   Hayakawa, Yoshihiro ^a   Takeda, Kazuyoshi ^b   Yagita, Hideo ^b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 15; INTERLEUKIN 2; APOPTOSIS REGULATORY PROTEIN; FAS LIGAND; FASL PROTEIN, MOUSE; FASLG PROTEIN, HUMAN; GAMMA INTERFERON; IMMUNOGLOBULIN RECEPTOR; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; TNFSF10 PROTEIN, HUMAN; TNFSF10 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

BONE MARROW TRANSPLANTATION; CANCER INHIBITION; CANCER THERAPY; CLINICAL TRIAL; HOST RESISTANCE; HUMAN; IMMUNE SYSTEM; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR REJECTION; ADOPTIVE IMMUNOTHERAPY; ALLOTRANSPLANTATION; ANIMAL; ANTIGEN PRESENTATION; APOPTOSIS; BIOLOGICAL MODEL; CYTOTOXICITY; IMMUNOLOGY; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; METHODOLOGY; MOUSE; NEOPLASM; PHYSIOLOGY; TRANSPLANTATION; TUMOR ESCAPE;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BONE MARROW TRANSPLANTATION; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; HUMANS; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; KILLER CELLS, NATURAL; MEMBRANE GLYCOPROTEINS; MICE; MODELS, IMMUNOLOGICAL; NEOPLASMS; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSPLANTATION, HOMOLOGOUS; TUMOR ESCAPE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036831613     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc928     Document Type: Review

References (154)

1. Cerwenka, A. & Lanier, L. L. Natural killer cells, viruses and cancer. Nature Rev. Immunol. 1, 41-49 (2001).
2. Wiltrout, R. H. et al. Augmentation of organ-associated natural killer activity by biological response modifiers. Isolation and characterization of large granular lymphocytes from the liver. J. Exp. Med. 160, 1431-1449 (1984).
3. Fogler, W. E. et al. NK cell infiltration into lung, liver, and subcutaneous B16 melanoma is mediated by VCAM-1/ VLA-4 interaction. J. Immunol. 156, 4707-4714 (1996).
4. Biron, C. A. Activation and function of natural killer cell responses during viral infections. Curr. Opin. Immunol. 9, 24-34 (1997).
5. Glas, R. et al. Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype. An adaptive component of NK cell-mediated responses. J. Exp. Med. 191, 129-138 (2000).
6. Cooper, M. A., Fehniger, T. A. & Caligiuri, M. A. The biology of human natural killer-cell subsets. Trends Immunol. 22, 633-640 (2001).
7. Colucci, F., Di Santo, J. P. & Leibson, P. J. Natural killer cell activation in mice and men: different triggers for similar weapons? Nature Immunol. 3, 807-813 (2002).
8. Cooper, M. A. et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 97, 3146-3151 (2001).
9. Koo, G. C., Dumont, F. J., Tutt, M., Hackett, J. Jr & Kumar, V. The NK-1.1(-) mouse: a model to study differentiation of murine NK cells. J. Immunol. 137, 3742-3747 (1986).
10. Smyth, M. J., Crowe, N. Y. & Godfrey, D. I. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int. Immunol. 13, 459-463 (2001).
11. Riccardi, C., Santoni, A., Barlozzari, T., Puccetti, P. & Herberman, R. B. In vivo natural reactivity of mice against tumor cells. Int. J. Cancer 25, 475-486 (1980). An early and clear description of the natural activity of NK cells against tumour cells in vivo.
12. Gorelik, E., Rosen, B., Copeland, D., Weathedy, B. & Herberman, R. B. Evaluation of role of natural killer cells in radiation-induced leukemogenesis in mice. J. Natl. Cancer Inst. 72, 1397-1403 (1984).
13. Barlozzari, T. Reynolds, C. W. & Herberman, R. B. In vivo role of natural killer cells: involvement of large granular lymphocytes in the clearance of tumor cells in anti-asialo GM1-treated rats. J. Immunol. 131, 1024-1027 (1983).
14. Ljunggren, H. G. & Karre, K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J. Exp. Med. 162, 1745-1759 (1985). A selection of mouse lymphoma variants that lacked H-2 first illustrated the concept of NK cells recognizing 'missing-self' in vivo.
15. Karre, K., Ljunggren, H. G., Piontek, G. & Kiessling, R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319, 675-676 (1986).
16. van den Broek, M. F., Kagi, D., Zinkernagel, R. M. & Hengartner, H. Perforin dependence of natural killer cell-mediated tumor control in vivo. Eur. J. Immunol. 25, 3514-3516 (1995). The first demonstration that perforin is a major effector pathway used by NK cells to eliminate MHC class-I-deficient tumours in vivo.
17. Smyth, M. J., Kelly, J. M., Baxter, A. G., Korner, H. & Sedgwick, J. D. An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J. Exp. Med. 188, 1611-1619 (1998).
18. Smyth, M. J. et al. Perforin is a major contributor to NK cell control of tumor metastasis. J. Immunol. 162, 6658-6662 (1999).
19. Talmadge, J. E., Phillips, H., Schindler, J., Tribble, H. & Pennington, R. Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease. Cancer Res. 47, 5725-5732 (1987).
20. Trinchieri, G. Interleukin-12 a cytokine at the interface of inflammation and immunity. Adv. Immunol. 70, 83-243 (1998).
21. Wiltrout, R. H. et al. Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver. J. Immunol. 134, 4267-4275 (1985).
22. McClain, K. L. Immunodeficiency states and related malignancies. Cancer Treat. Res. 92, 39-61 (1997).
23. Smyth, M. J. et al. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 192, 755-760 (2000).
24. Shankaran, V. et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107-1111 (2001).
25. + cells in natural protection from chemical carcinogen-induced tumour initiation.
26. Haliotis, T., Ball, J. K., Dexter, D. & Roder, J. C. Spontaneous and induced primary oncogenesis in natural killer (NK)-cell-deficient beige mutant mice. Int. J. Cancer. 35, 505-513 (1985).
27. Erianne, G. S. et al. B cell lymphomas of C57L/J mice; the role of natural killer cells and T helper cells in lymphoma development and growth. Leuk. Res. 24, 705-718 (2000).
28. Miyauchi-Hashimoto, H. Okamoto, H., Tanaka, K. & Horio, T. Ultraviolet radiation-induced suppression of natural killer cell activity is enhanced in xeroderma pigmentosum group A (XPA) model mice. J. Invest. Dermatol. 112, 965-970 (1999).
29. Norris, P. G., Limb, G. A., Hamblin, A. S. & Hawk, J. L. Impairment of natural-killer-cell activity in xeroderma pigmentosum. N. Engl. J. Med. 319, 1668-1669 (1988).
30. Gaspar, A. A., Fleisher, T. A. & Kraemer, K. H. Impaired interferon production and natural killer cell activation in patients with the skin cancer-prone disorder, xeroderma pigmentosum. J. Clin. Invest. 92, 1135-1142 (1993).
31. Whiteside, T. L. & Herberman, R. B. Role of human natural killer cells in health and disease. Clin. Diagn. Lab. Immunol. 1, 125-133 (1994).
32. Whiteside, T. L., Vujanovic, N. L. & Herberman, R. B. Natural killer cells and tumor therapy. Curr. Top. Microbiol. Immunol. 230, 221-244 (1998).
33. Trapani, J. A., Davis, J., Sutton, V. R. & Smyth, M. J. Proapoptotic functions of cytotoxic lymphocyte granule constituents in vitro and in vivo. Curr. Opin Immunol. 12, 323-329 (2000).
34. Kagi, D. et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369, 31-37 (1994). Landmark paper that first described perforin-deficient mice and their lack of NK-cell-mediated cytolysis.
35. Smyth, M. J. et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 193, 661-670 (2001).
36. Kodama, T. et al. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur. J. Immunol. 29, 1390-1396 (1999).
37. Brandau, S. et al. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guerin-activated killer cells. Clin. Cancer Res. 6, 3729-3738 (2000).
38. van den Broek, M. E. et al. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med 184, 1781-1790 (1996).
39. Street, S. E. Trapani, J. A., MacGregor, D. & Smyth, M. J. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J. Exp. Med. 196, 129-134 (2002).
40. Davis, J. E., Smyth, M. J. & Trapani, J. A. Granzyme A- and B-deficient killer lymphocytes are defective in eliciting DNA fragmentation but retain potent in vivo anti-tumor capacity. Eur. J. Immunol. 31, 39-47 (2001).
41. Ashkenazi, A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nature Rev. Cancer 2, 420-430 (2002).
42. Kayagaki, N. et al. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J. Immunol. 163, 1906-1913 (1999).
43. Takeda, K. et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nature Med. 7, 94-100 (2001). The first demonstration that NK-cell TRAIL has a physiological function as a tumour suppressor.
44. Cretney, E. et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice J. Immunol. 168, 1356-1361 (2002).
45. Takeda, K. et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 195, 161-169 (2002).
46. Kronenberg, M. & Gapin, L. The unconventional lifestyle of NKT cells. Nature Rev. Immunol. 2, 557-568 (2002).
47. - tumor cells. Blood 92, 4248-4255 (1998).
48. Screpanti, V., Wallin, R. R. Ljunggren, H. G. & Grandien, A. A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells J. Immunol. 167, 2068-2073 (2001).
49. Loza, M. J., Zamai, L., Azzoni, L., Rosati, E. & Perussia, B. Expression of type 1 (interferon gamma) and type 2 (interleukin-13, interleukin-5) cytokines at distinct stages of natural killer cell differentiation from progenitor cells. Blood 99, 1273-1281 (2002).
50. Biron, C. A., Nguyen, K. B., Pien, G. C., Cousens, L. P. & Salazar-Mather, T. P. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 17, 189-220 (1999).
51. Street, S. E. Cretney, E. & Smyth, M. J. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 97, 192-197 (2001).
52. Yao, L. et al. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 93, 1612-1621 (1999).
53. Smyth, M. J. et al. Sequential production of interferon-gamma by NK1.1(+) T cells end natural killer cells is essential for the antimetastatic effect of alpha-galactovceramide. Blood 99, 1259-1266 (2002).
54. Hayakawa, Y. et al. IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood 100, 1728-1733 (2002).
55. Cifone, M. G. et al. Interleukin-2-activated rat natural killer cells express inducible nitric oxide synthase that contributes to cytotoxic function and interferon-gamma production. Blood 93, 3876-3884 (1999).
56. Furuke, K. et al. Human NK cells express endothelial nitric oxide synthase, and nitric oxide protects them from activation-induced cell death by regulating expression of TNF-alpha. J. Immunol. 163, 1473-1480 (1999).
57. Leibson, P. J. Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity 6, 655-661 (1997).
58. Yokoyama, W. M. et al. A family of murine NK cell receptors specific for target cell MHC class I molecules. Semin. Immunol. 7, 89-101 (1995).
59. Takei, F., Brennan, J. & Meger, D. L. The Ly-49 family: genes, proteins and recognition of class I MHC. Immunol. Rev. 155, 67-77 (1997).
60. Lanier, L. L. NK cell receptors. Annu. Rev. Immunol. 16, 359-393 (1998).
61. Long, E. O. et al. Inhibition of natural killer cell activation signals by killer cell immunoglobulin-like receptors (CD158). Immunol. Rev. 181, 223-233 (2001).
62. O'Callaghan, C. A. Molecular basis of human natural killer cell recognition of HLA-E (human leucocyte antigen-E) and its relevance to clearance of pathogen-infected and tumour cells. Clin. Sci 99, 9-17 (2000).
63. Liao, N. S., Bix, M., Zijlstra, M., Jaenisch, R. & Raulet, D. MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity. Science 253, 190-202 (1991).
64. Rugged, L., Capanni, M. Martelli, M. F. & Velardi, A. Cellular therapy: exploiting NK cell alloreactivity in transplantation. Curr. Opin. Hematol 8, 355-359 (2001).
65. Rugged, L. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097-2100 (2002). Recipients of MHC-mismatched transplants display NK-cell alloreactivity that eliminates leukaemia relapse, prevents graft rejection and protects patients against graft versus host disease. A beautiful demonstration of how new knowledge about NK-cell receptors for MHC class I can pave the way for effective immunotherapy using NK cells.
66. Bekker, A. B., Phillips, J. H., Figdor, C. G. & Lanier, L. L. Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL. J. Immunol. 160, 5239-5245 (1998).
67. Koh, C. Y. et al. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 97, 3132-3137 (2001).
68. Smith, K. M., Wu, J., Bakker, A. B., Phillips, J. H. & Lanier, L. L. Ly-49D and Ly-49H associate with mouse DAP12 and form activating receptors. J. Immunol. 161, 7-10 (1998).
69. Idris, A. H., Iizuka, K., Smith, H. R., Scalzo, A. A. & Yokoyama, W. M. Genetic control of natural killing and in vivo tumor elimination by the Chok locus. J. Exp. Med. 188, 2243-2256 (1998).
70. Idris, A. H. et al. The natural killer gene complex genetic locus Chok encodes Ly-49D, a target recognition receptor that activates natural killing Proc. Natl Acad. Sci. USA 96, 6330-6335 (1999).
71. Kubota, A., Lian, R. H., Lohwasser, S., Salcedo, M. & Takei, F. IFN-gamma production and cytotoxicity of IL-2-activated murine NK cells are differentially regulated by MHC class I molecules. J. Immunol. 163, 6488-6493 (1999).
72. Le Drean, E. et al. Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases. Eur. J. Immunol. 28, 264-276 (1998).
73. Moser, J. M., Gibbs, J., Jensen, P. E. & Lukacher, A. E. CD94-NKG2A receptors regulate antiviral CD8(+) T cell responses. Nature Immunol. 3, 189-195 (2002).
74. low cells from NK-mediated lysis in vivo. J. Immunol. 165, 6142-6147 (2000).
75. Moretta, A. et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19, 197-223 (2001).
76. Lanier, L. L. On guard: activating NK cell receptors. Nature Immunol. 2, 23-27 (2001).
77. Sivori, S. et al. p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J. Exp. Med. 186, 1129-1136 (1997). First decription of a new family of natural cytotoxicity receptors on NK cells that have a key role in non-MHC-restricted cytolysis.
78. Vitale, M. et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J. Exp. Med. 187, 2065-2072 (1998).
79. Moretta, A., Biassoni, R., Bottino, C., Mingari, M. C. & Moretta, L. Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol. Today 21, 228-234 (2000).
80. Tomasello, E. et al. Combined natural killer cell and denritic cell functional deficiency in KARAP/DAP 12 loss-of-function mutant mice. Immunity 13, 355-364 (2000).
81. Bauer, S. et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285, 727-729 (1999). Demonstration that NKG2D recognizes stress-inducible MICA, a distant homologue of MHC class I, and previously shown to function as an antigen for γδ T cells and frequently expressed in epithelial tumours. These data first indicated an activating-immunoreceptor-MHC-ligand interaction that might promote antitumour NK- and T-cell responses.
82. Wu, J. et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285, 730-732 (1999).
83. Groh, V. et al. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl Acad. Sci. USA 93, 12445-12450 (1996).
84. Groh, V. et al. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc. Natl Acad. Sci. USA 96, 6879-6884 (1999).
85. Cosman, D. et al. ULBPS, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14, 123-133 (2001).
86. Majarkannan, S. et al. The molecular and functional characterization of a dominant minor H antigen, H60. J. Immunol. 161, 3501-3509 (1998).
87. Cerwenka, A. et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 12, 721-727 (2000). First description of mouse GPI-anchored cell-surface proteins that function as ligands for the activating NKG2D receptor and confer target susceptibilfty to NK-cell attack.
88. Diefenbach, A., Jamieson, A. M., Liu, S. D., Shastri, N. & Raulet, D. H. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nature Immunol. 1, 119-126 (2000).
89. Groh, V., Steinle, A., Bauer, S. & Spies, T. Recognition of stress-induced MHC molecules by intestinal epithelial γδ T cells. Science 279, 1737-1740 (1998).
90. Vetter, C. S. et al. Expression of stress-induced MHC class I related chain molecules on human melanoma. J. Invest. Dermatol 118, 600-605 (2002).
91. + T cells in vivo.
92. Cerwenka, A. Baron, J. L. & Lanier, L. L. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl Acad. Sci. USA 98, 11521-11526 (2001).
93. Girardi, M. et al. Regulation of cutaneous malignancy by γδ T cells. Science 294, 605-609 (2001).
94. Kennedy, C. et al. MICA gene polymorphism is not associated with an increased risk for skin cancer. J. Invest. Dermatol. 118, 686-691 (2002).
95. Ghaderi, M. et al. Tumor necrosis factor A and MHC class I chain related gene A (MIC-A) polymorphisms in Swedish patients with cervical cancer. Hum. Immunol. 62, 1153-1158 (2001).
96. Pende, D. et al. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur. J. Immunol. 31, 1076-1086 (2001).
97. Clynes, R. A., Towers, T. L., Presta, L. G. & Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Med. 6, 443-446 (2000).
98. Wilson, J. L. et al. NK cell triggering by the human costimulatory molecules CD80 and CD86. J. Immunol. 163, 4207-4212 (1999).
99. Galea-Lauri, J. et al. Expression of a vaiant of CD28 on a subpopulation of human NK cells: implications for B7-mediated stimulation of NK cells. J. Immunol. 163, 62-70 (1999).
100. Geldhof, A. B. et al. Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity. Cancer Res. 55, 2730-2733 (1995).
101. Kelly, J. M., Takeda, K., Darcy, P. K., Yagita, H. & Smyth, M. J. A role for IFN-gamma in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo. J. Immunol. 168, 4472-4479 (2002). Direct demonstration that NK-cell-mediated rejection of tumours via CD27-CD70 co-stimulatory interactions subsequently evoke the development of tumour-specific cytotoxic and T helper type 1 responses, providing a key link between innate NK-cell responses and adaptive T-cell immunity.
102. +, murine myelogenous leukemia. Blood 99, 2146-2153 (2002).
103. Lang, S. Vujanovic, N. L., Wollenberg, B. & Whiteside, T. L. Absence of B7.1-CD28/CTLA-4-mediated co-stimulation in human NK cells. Eur. J. Immunol. 28, 780-786 (1998).
104. Sugita, K. et al. Participation of the CD27 antigen in the regulation of IL-2-activated human natural killer cells. J. Immunol. 149, 1199-1203 (1992).
105. Takeda, K. et al. CD27-mediated activation of murine NK cells. J. Immunol. 164, 1741-1745 (2000).
106. Kelly, J. M. et al. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nature Immunol. 3, 83-90 (2002).
107. Sivori, S. et al. 2B4 functions as a co-receptor in human NK cell activation. Eur. J. Immunol. 30, 787-793 (2000).
108. Sivon, S. et al. Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation. Proc. Natl Acad. Sci. USA 99, 4526-4531 (2002).
109. Tangye, S. G. Phillips, J. H., Lanier, L. L. & Nichols, K. E. Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome. J. Immunol. 165, 2932-2936 (2000).
110. Nakajima, A. et al. Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7. J. Immunol. 161, 1901-1907 (1998).
111. Takeda, K. et al. Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12. Int. Immunol. 12, 909-914 (2000).
112. Duda, D. G. et al. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res. 60, 1111-1116 (2000).
113. Smyth, M. J., Taniguchi, M. & Street, S. E. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J. Immunol. 165, 2665-2670 (2000).
114. Fernandez, N. C. et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nature Med. 5, 405-411 (1999). Milestone paper illustrating that dendritic cells can trigger the innate, NK-cell-mediated antitumour immunity.
115. Waldmann, T. A., Dubois, S. & Tagaya, Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 14, 105-110 (2001).
116. Fehniger, T. A. & Caligiud, M. A. Interleukin 15: biology and relevance to human disease. Blood 97, 14-32 (2001).
117. Yajima, T. et al. Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response. Int. J. Cancer 99, 573-578 (2002).
118. Lynch, D. H. et al. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nature Med. 3, 625-631 (1997).
119. Peron, J. M. et al. FLT3-ligand administration inhibits liver metastases: role of NK cells. J. Immunol. 161, 6164-6170 (1998).
120. Pawlowska, A. B. et al. In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice. Blood 97, 1474-1482 (2001).
121. Zheng, L. M. et al. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J. Exp. Med. 184, 579-584 (1996).
122. Moore, R. J. et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nature Med. 5, 828-831 (1999).
123. Pilaro, A. M. et al. TNF-alpha is a principal cytokine involved in the recruitment of NK cells to liver parenchyma. J. Immunol. 153, 333-342 (1994).
124. Kasaian, M. T. et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 16, 559-569 (2002).
125. + NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J. Immunol. 166, 6477-6482 (2001).
126. Inngierdingen, M., Damaj, B. & Maghazachi, A. A. Expression and regulation of chemokine receptors in human natural killer cells. Blood 97, 367-375 (2001).
127. Yoneda, O. et al. Fractalkine-mediated endothelial cell injury by NK cells. J. Immunol. 164, 4055-4062 (2000).
128. + cytotoxic effector lymphocytes that are defned by CX3CR1 expression. J. Immunol. 168, 6173-6180 (2002).
129. Piccioli, D., Sbrana, S., Melandri, E. & Valiante, N. M. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J. Exp. Med. 195, 335-341 (2002).
130. Feriazzo, G. et al. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J. Exp. Med. 195, 343-351 (2002).
131. Gerosa, F. et al. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 195. 327-333 (2002).
132. Maki, G. et al. Induction of sensitivity to NK mediated cytotoxicity by TNF-alpha treatment: possible roles of ICAM-3 and CD44. Leukemia 12, 1565-1572 (1998).
133. Costello, R. T. et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 15, 3661-3667 (2002).
134. Maraninchi, D. et al. A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia. Leuk. Lymph 31, 343-349 (1998).
135. Chang, E. & Rosenberg, S. A. Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2-based therapy. J. Immunother. 24, 88-90 (2001).
136. Mulatero, C. W. et al. A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma. Lung Cancer 31, 67-72 (2001).
137. Benyunes, M. C. et al. Interleukin-2 with or without lymphokine-activated killer cells as consolidative Immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant. 12, 159-163 (1993).
138. Hayes, R. L. et al Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 76, 840-852 (1995).
139. Rosenberg, S. A. et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Nat. Cancer Inst. 85, 622-632 (1993).
140. Margolin, K. A. Interleukin-2 in the treatment of renal cancer Semin. Oncol. 27, 194-203 (2000).
141. Semino, C. et al. Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience. Anticancer Res. 19, 5645-5649 (1999).
142. Burns, L. J. et al. Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer. Exp. Hematol. 28, 96-103 (2000).
143. Caligiuri, M. A. et al. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J. Exp. Med. 171, 1509-1526 (1990).
144. Buzio, C. et al. Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma. Cancer 92, 2286-2296 (2001).
145. Carson, W. E. et al. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur. J. Immunol. 31, 3016-3025 (2001).
146. Kossman, S. E., Scheinberg, D. A. Jurcic, J. G., Jimenez, J. & Caron, P. C. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia. Clin. Cancer Res. 5, 2748-2755 (1999).
147. da Costa, L., Renner, C., Hartmann, F. & Pfreundschuh, M. Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease. Cancer Chemother. Pharmacol. 46, S33-S36 (2000).
148. Renner C. et al. Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody. Cancer. Immunol. Immunother. 49, 173-180 (2000).
149. Gong, J. H., Maki, G. & Klingemann, H. G. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8, 652-658 (1994).
150. Yan, Y. et al. Antileukemia activity of a natural killer cell line against human leukemias. Clin. Cancer Res. 4, 2859-2868 (1998).
151. Tonn, T., Becker, S., Esser, R., Schwabe, D. & Selfried, E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J. Hematother. Stem Cell Res. 10, 535-544 (2001).
152. Ruggeri, L. et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94, 333-339 (1999).
153. Davies, S. M. et al. An evaluation of KIR ligand incompatability in mismatched unrelated donor hematopoietic transplants. Blood 5 Jul 2002 [epub ahead of print].
154. Groh, V. et al. Tumour-derived soluble MC ligands impair expression of NKG2D and T-cell activation. Nature 419, 734-738 (2002).